8-KEarnings & ResultsRegulation FDExhibits & Filings

Elevance Health, Inc. 8-K Report, Financial Results (Jan 30, 2019)

Filed January 30, 2019For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on January 30, 2019, primarily to disclose the release of its fourth quarter and full-year 2018 financial results and a significant operational update regarding its pharmacy benefit management (PBM) services. The company announced the termination of its PBM services agreement with Express Scripts, Inc., effective March 1, 2019. This strategic move indicates a shift in Elevance Health's approach to managing its prescription drug benefits, likely to bring these operations in-house or transition to a different provider, which could have substantial implications for cost management and operational control. The accompanying press release, furnished as an exhibit, would contain the detailed financial performance for the period ended December 31, 2018. Investors should pay close attention to the details within that press release (Exhibit 99.1) for specific earnings figures, revenue growth, profitability metrics, and any forward-looking guidance provided by the company. The termination of the Express Scripts contract is a major event that warrants careful consideration of its potential impact on future cost structures, service delivery, and overall financial performance.

Key Highlights

  • 1Elevance Health (then Anthem, Inc.) announced the termination of its Pharmacy Benefits Management (PBM) services agreement with Express Scripts, Inc.
  • 2The termination of the Express Scripts PBM agreement is effective March 1, 2019.
  • 3The 8-K report includes financial results for the fourth quarter ended December 31, 2018, furnished via press release (Exhibit 99.1).
  • 4The press release contains detailed financial results and potentially forward-looking statements regarding future performance.
  • 5This action signals a significant strategic shift in how Elevance Health manages its prescription drug benefits.
  • 6Investors are urged to review the press release (Exhibit 99.1) for comprehensive financial details and operational implications.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Elevance Health's (then Anthem, Inc.) fourth quarter and full-year 2018 financial results via a press release and to disclose the termination of its pharmacy benefits management services agreement with Express Scripts, effective March 1, 2019.

Terminating the contract with Express Scripts represents a significant strategic decision. It suggests Elevance Health plans to bring PBM services in-house or switch to a different provider. This could lead to greater control over prescription drug costs, potential cost savings, and changes in operational efficiency and service delivery for its members.

The detailed financial results for the fourth quarter ended December 31, 2018, are provided in the press release dated January 30, 2019, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated herein by reference.

Potential risks include disruption in PBM services during the transition, financial penalties if contractual obligations are not met, inability to meet customer demands, and potential sanctions from governmental entities like CMS. The company's extensive list of forward-looking statements also highlights numerous other risks and uncertainties, including regulatory changes, healthcare cost trends, competition, and litigation.